Back to Search
Start Over
Anti-VEGF Therapy in Myopic CNV.
- Source :
-
Current drug targets [Curr Drug Targets] 2021; Vol. 22 (9), pp. 1054-1063. - Publication Year :
- 2021
-
Abstract
- In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic myopia. The natural course of mCNV can result in expanding macular atrophy and /or fibrosis, leading to irreversible visual loss after 5 years. Retinal multimodal imaging is mandatory for early diagnosis and monitoring of the disease during treatment. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as the first-line treatment option for mCNV. Prompt treatment of active mCNV with intravitreal anti-VEGF therapy has been demonstrated to be effective in terms of visual outcome improvements reducing the occurrence of late-stage complications.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Bevacizumab therapeutic use
Humans
Intravitreal Injections
Ranibizumab
Visual Acuity
Choroidal Neovascularization drug therapy
Myopia, Degenerative complications
Myopia, Degenerative drug therapy
Vascular Endothelial Growth Factor A antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5592
- Volume :
- 22
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Current drug targets
- Publication Type :
- Academic Journal
- Accession number :
- 33511955
- Full Text :
- https://doi.org/10.2174/1389450122999210128180725